Murli Krishna Pharma's Mission to End Anemia's Grip on Indian Communities

Murli Krishna Pharma Pvt. Ltd, two-decade old Indian pharmaceutical organization, pioneered in combating anemia in Indian communities. With a focus on public health, the company has innovated “Transdermal Lotion” to effectively tackle iron deficiency anemia. Its manufacturing plant, endorsed by the European Union, WHO, GCC, and Jordanian FDA, produces top-quality Pre-Finished Formulation Intermediates and Finished Dosage forms. 

Adhering to WHO-GMP guidelines, Murli Krishna Pharma ensures international standard compliance, delivering superior products for anemia treatment. Its commitment to quality underscores its mission to provide cutting-edge solutions for anemia, marking them as a leader in addressing this prevalent health concern in India.

Anemia Gripping Indian Communities: Overview

Anemia is a significant public health challenge in Indian communities, disproportionately affecting women and children. According to the National Family Health Survey (NFHS-5) data, over 57% of women aged 15-49 years and around 68% of children aged 6-59 months are anemic. This condition is primarily caused by nutritional deficiencies, particularly iron, which is essential for hemoglobin production.

In rural areas, the prevalence is even higher due to limited access to nutritious food, healthcare facilities, and education about dietary needs. Cultural practices and poverty exacerbate the situation, as many families prioritize caloric intake over nutritional value, leading to diets deficient in iron, vitamin B12, and folic acid.

Anemia in children can result in impaired cognitive and physical development, affecting their educational outcomes and overall quality of life. For women, especially those of reproductive age, anemia increases the risk of complications during pregnancy and childbirth, contributing to maternal mortality rates.

Murli Krishna Pharma’s Mission to End Anemia with Transdermal Lotion

Murli Krishna Pharma, a leading pharmaceutical company in India, has made significant strides in addressing the pressing issue of anemia through the development of an innovative transdermal lotion. Considering the National Family Health Survey (NFHS-5) data, over 57% of women aged 15-49 years and around 68% of children aged 6-59 months in India are affected by anemia, making it a critical public health concern. 

Murli Krishna Pharma’s transdermal lotion offers a unique and non-invasive approach to combating iron deficiency anemia. By applying the lotion directly to the skin, iron is absorbed through the bloodstream, bypassing the common gastrointestinal side effects associated with oral iron supplements. This innovative delivery system ensures better compliance and efficiency in increasing hemoglobin levels, particularly in areas where anemia prevalence is highest.

The company’s mission is driven by the goal of making this advanced treatment accessible to the masses, especially in rural and underserved areas. Murli Krishna Pharma’s transdermal lotion is designed to be user-friendly and affordable, eliminating the need for medical supervision and reaching a broader population. By focusing on affordability and accessibility, the company aims to significantly reduce the incidence of anemia, improve public health outcomes, and enhance the quality of life for millions of Indians.

Murli Krishna Pharma’s Contribution to ‘Anemia Mukt Bharat’

Murli Krishna Pharma has made significant contributions to the ‘Anemia Mukt Bharat’ initiative, a comprehensive flagship program launched by the Indian government to tackle the high prevalence of anemia across all age groups. Some of their key contributions include:

  • Development of a Transdermal Iron Lotion: Murli Krishna Pharma pioneered the introduction of a transdermal lotion as a branded formulation for treating anemia through metered dose administration. This innovative delivery system offers a convenient and effective method for managing iron deficiency anemia, aligning with the ‘Anemia Mukt Bharat’ initiative’s goal of providing accessible treatment options.
  • Raising awareness and promoting preventive measures: The company engages in extensive community outreach and education programs to raise awareness about the importance of anemia prevention and the benefits of their transdermal solution. These efforts support the ‘Anemia Mukt Bharat’ initiative in promoting healthy practices and early detection of anemia.
  • Collaborating with healthcare providers and government agencies: Murli Krishna Pharma collaborates with healthcare providers and government agencies to ensure the widespread distribution and adoption of their anemia treatment products. By providing training and resources to healthcare workers, the company helps facilitate better diagnosis and treatment of anemia, contributing to the overall effectiveness of the ‘Anemia Mukt Bharat’ campaign.
  • Focusing on affordability and accessibility: The company’s mission is driven by the goal of making their advanced anemia treatment accessible to the masses, particularly in rural and underserved areas where anemia prevalence is highest. By prioritizing affordability and user-friendliness, Murli Krishna Pharma aims to reach a broader population and significantly reduce the incidence of anemia in line with the objectives of ‘Anemia Mukt Bharat’.

Through its innovative products, strategic partnerships, and community engagement activities, Murli Krishna Pharma continues to play a vital role in supporting the ‘Anemia Mukt Bharat’ initiative and working towards a healthier, anemia-free India.